A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated from a Rhesus Macaque
- 15 December 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (24), 12738-12750
- https://doi.org/10.1128/jvi.01441-09
Abstract
We created a hybrid adeno-associated virus (AAV) from two related rhesus macaque isolates, called AAVrh32.33, and evaluated it as a vaccine carrier for human immunodeficiency virus type 1 (HIV-1) and type A influenza virus antigens. The goal was to overcome the limitations of vaccines based on other AAVs, which generate dysfunctional T-cell responses and are inhibited by antibodies found in human sera. Injection of a Gag-expressing AAVrh32.33 vector into mice resulted in a high-quality CD8 + T-cell response. The resulting Gag-specific T cells express multiple cytokines at high levels, including interleukin-2, with many having memory phenotypes; a subsequent boost with an adenovirus vector yielded a brisk expansion of Gag-specific T cells. A priming dose of AAVrh32.33 led to high levels of Gag antibodies, which exceed levels found after injection of adenovirus vectors. Importantly, passive transfer of pooled human immunoglobulin into mice does not interfere with the efficacy of AAVrh32.33 expressing nucleoproteins from influenza virus, as measured by protection to a lethal dose of influenza virus, which is consistent with the very low seroprevalence to this virus in humans. Studies of macaques with vectors expressing gp140 from HIV-1 (i.e., with AAVrh32.33 as the prime and simian adenovirus type 24 as the boost) demonstrated results similar to those for mice with high-level and high-quality CD8 + T-cell responses to gp140 and high-titered neutralizing antibodies to homologous HIV-1. The biology of this novel AAV hybrid suggests that it should be a preferred genetic vaccine carrier, capable of generating robust T- and B-cell responses.This publication has 52 references indexed in Scilit:
- Efficacy of Severe Acute Respiratory Syndrome Vaccine Based on a Nonhuman Primate Adenovirus in the Presence of Immunity Against Human AdenovirusHuman Gene Therapy, 2006
- Long-Term Efficacy of Adeno-Associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and MiceHuman Gene Therapy, 2006
- Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1Journal of Virology, 2006
- Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID miceBlood, 2006
- Tolerance Induction by Viral In Vivo Gene TransferClinical Medicine & Research, 2005
- Comparison of Adenoviral and Adeno-Associated Viral Vectors for Pancreatic Gene DeliveryIn VivoHuman Gene Therapy, 2004
- Immune Response Against Gene Therapy Vectors: Influence of Synovial Fluid on Adeno-Associated Virus Mediated Gene Transfer to ChondrocytesJournal of Clinical Immunology, 2004
- Recent Advances in the Development of HIV-1 Vaccines Using Replication-Incompetent Adenovirus VectorsAnnual Review of Medicine, 2004
- Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1Blood, 2004
- Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus ImmunityJournal of Virology, 2003